Full Text View
Tabular View
No Study Results Posted
Related Studies
Eye Injections of Triamcinolone Acetonide for Retinal Blood Vessel Disorders
This study has been completed.
Study NCT00071227   Information provided by National Institutes of Health Clinical Center (CC)

First Received on October 15, 2003.   Last Updated on August 16, 2007   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Macular Degeneration
Retinal Vein Occlusion
Additional conditions recognized in this trial
Vascular Diseases
More general conditions related to this trial
Cardiovascular Diseases
Embolism and Thrombosis
Eye Diseases
Retinal Degeneration
Retinal Diseases
Thrombosis
Venous Thrombosis
Interventions listed in this trial
Triamcinolone Acetonide (TAC-PF)
Additional drug interventions recognized in this trial
Triamcinolone
Triamcinolone Acetonide
Triamcinolone diacetate
Triamcinolone hexacetonide
More general drug interventions related to this trial
Anti-Inflammatory Agents
Enzyme Inhibitors
Glucocorticoids
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Immunologic Factors
Immunosuppressive Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Sponsors listed in this trial
National Eye Institute (NEI)


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services